𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Landmark trials in endocrine adjuvant therapy for breast carcinoma

✍ Scribed by William Gradishar

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
78 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Progress in endocrine therapy for breast
Progress in endocrine therapy for breast carcinoma
✍ Gabriel N. Hortobagyi πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 79 KB πŸ‘ 2 views

As Cancer commemorates 50 years of continuous publication, this article is one of a series of summaries on the current status of some of the oncologic issues reported in the first volume in 1948.

Adjuvant systemic therapy for male breas
Adjuvant systemic therapy for male breast carcinoma
✍ Sharon H. Giordano; George H. Perkins; Kristine Broglio; Sherry G. Garcia; Lavin πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 136 KB

## Abstract ## BACKGROUND In the current study, the authors describe the M. D. Anderson experience with adjuvant systemic therapy in male breast carcinoma patients. ## METHODS A total of 156 men with a diagnosis of breast carcinoma registered and were treated at the M. D. Anderson Cancer Center

A randomized trial of adjuvant endocrine
A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors
✍ Yasuo Nomura; Hideya Tashiro; Kazufumi Hisamatsu; Katsuko Shinozuka πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 660 KB

Based on estrogen receptor (ER) status and menopausal status, operable breast cancer (International Union Against Cancer [UICC] Stage I, II, and III) patients were randomized for adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy, and the effects on the disease-free survival (DFS)

Refined measurement of outcome for adjuv
Refined measurement of outcome for adjuvant breast carcinoma therapy
✍ John W. Gamel; Gianni Bonadonna; Pinuccia Valagussa; Michael J. Edwards πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 102 KB

## Abstract ## BACKGROUND Traditional nonparametric statistical methods do not provide a quantitative measure of the lifetime benefit from adjuvant therapy. This deficiency makes it difficult to determine the long‐term difference in impact between the two treatment arms of a clinical trial. ## ME